Toll Free: 1-888-928-9744

Shigella Infections (Shigellosis) - Pipeline Review, H1 2016

Published: Apr 20, 2016 | Pages: 53 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Shigella Infections (Shigellosis) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Shigella Infections (Shigellosis) - Pipeline Review, H1 2016', provides an overview of the Shigella Infections (Shigellosis) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Shigella Infections (Shigellosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Shigella Infections (Shigellosis) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Shigella Infections (Shigellosis)
- The report reviews pipeline therapeutics for Shigella Infections (Shigellosis) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Shigella Infections (Shigellosis) therapeutics and enlists all their major and minor projects
- The report assesses Shigella Infections (Shigellosis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Shigella Infections (Shigellosis)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Shigella Infections (Shigellosis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Shigella Infections (Shigellosis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Content 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Shigella Infections (Shigellosis) Overview 7 Therapeutics Development 8 Pipeline Products for Shigella Infections (Shigellosis) - Overview 8 Pipeline Products for Shigella Infections (Shigellosis) - Comparative Analysis 9 Shigella Infections (Shigellosis) - Therapeutics under Development by Companies 10 Shigella Infections (Shigellosis) - Therapeutics under Investigation by Universities/Institutes 11 Shigella Infections (Shigellosis) - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Shigella Infections (Shigellosis) - Products under Development by Companies 14 Shigella Infections (Shigellosis) - Products under Investigation by Universities/Institutes 15 Shigella Infections (Shigellosis) - Companies Involved in Therapeutics Development 16 Anacor Pharmaceuticals, Inc. 16 GlaxoSmithKline Plc 17 Microbiotix, Inc. 18 Protein Potential, LLC 19 Visterra, Inc. 20 Shigella Infections (Shigellosis) - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Combination Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 (shigella + typhoid) vaccine - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 1790GAHB - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 GVXNSD-133 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 INX-201 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 KKL-35 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 SC-599 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 SE-1 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 shigella vaccine - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 shigella vaccine - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 shigella vaccine - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 shigella vaccine 1 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Shigetec - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecule for Shigellosis - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 VIS-GMN - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Shigella Infections (Shigellosis) - Recent Pipeline Updates 45 Shigella Infections (Shigellosis) - Dormant Projects 46 Shigella Infections (Shigellosis) - Discontinued Products 47 Shigella Infections (Shigellosis) - Product Development Milestones 48 Featured News & Press Releases 48 Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine 48 Feb 20, 2013: NIH-Funded Researchers Begin Trial of Shigella Vaccine Candidates 48 Jan 27, 2012: IVI Granted Two U.S. Patents On Dysentery Vaccine Inventions 49 Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease 50 Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine 51 Feb 15, 2007: IVI Scientists Develop New Laboratory Animal Model For Shigella 51 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables
Number of Products under Development for Shigella Infections (Shigellosis), H1 2016 8 Number of Products under Development for Shigella Infections (Shigellosis) - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Shigella Infections (Shigellosis) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 16 Shigella Infections (Shigellosis) - Pipeline by GlaxoSmithKline Plc, H1 2016 17 Shigella Infections (Shigellosis) - Pipeline by Microbiotix, Inc., H1 2016 18 Shigella Infections (Shigellosis) - Pipeline by Protein Potential, LLC, H1 2016 19 Shigella Infections (Shigellosis) - Pipeline by Visterra, Inc., H1 2016 20 Assessment by Monotherapy Products, H1 2016 21 Assessment by Combination Products, H1 2016 22 Number of Products by Stage and Target, H1 2016 24 Number of Products by Stage and Mechanism of Action, H1 2016 25 Number of Products by Stage and Route of Administration, H1 2016 27 Number of Products by Stage and Molecule Type, H1 2016 29 Shigella Infections (Shigellosis) Therapeutics - Recent Pipeline Updates, H1 2016 45 Shigella Infections (Shigellosis) - Dormant Projects, H1 2016 46 Shigella Infections (Shigellosis) - Discontinued Products, H1 2016 47


List of Figures
Number of Products under Development for Shigella Infections (Shigellosis), H1 2016 8 Number of Products under Development for Shigella Infections (Shigellosis) - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Products, H1 2016 13 Assessment by Monotherapy Products, H1 2016 21 Number of Products by Targets, H1 2016 23 Number of Products by Stage and Top 10 Targets, H1 2016 23 Number of Products by Routes of Administration, H1 2016 26 Number of Products by Stage and Routes of Administration, H1 2016 26 Number of Products by Molecule Types, H1 2016 28 Number of Products by Stage and Molecule Types, H1 2016 28

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likely

Read More...

Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet o

Read More...

Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population i

Read More...

Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehi

Read More...

North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption rat

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify